Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
Jürgen Floege, MD
Potassium Binders: Safety Comes First!
Ellie Kelepouris, MD, FACP, FAHA
Javed Butler, MD, MPH, MBA
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
James Burton, DM, FRCP
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Patrick Rossignol, MD, PhD
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
The Critical Interplay: CKD, HF, and HyperkaleAmia
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Treatment Revolution in IgA Nephropathy
Shikha Wadhwani, MD
Dana Rizk, MD
Difelikefalin: Managing CKD-aP for Improved Quality of Life
Jörg Latus, MD
IgA Nephropathy Updates: Evolving Guidelines and Practical Strategies
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Improving CKD Patient Outcomes with SGLT2 Inhibitors
Gates B. Colbert, MD
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Lucio Manenti, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.